Cape Town, South Africa

University of Cape Town

www.uct.ac.za
Cape Town, South Africa

The University of Cape Town is a public research university located in Cape Town in the Western Cape province of South Africa. UCT was founded in 1829 as the South African College, and is the oldest university in South Africa and the second oldest extant university in Africa. The language of instruction is English. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Cape Town | Date: 2017-02-01

The invention describes a membrane electrode assembly for use as a transport layer in polymer electrolyte fuel cells, the assembly comprising a porous metal gas diffusion layer (GDL) (20) and a catalyst layer (40) with a microporous layer (MPL) (30) interposed between them, the MPL (30) being constructed to fill the pores of the GDL (20) and coat the surface thereof.


Patent
University of Cape Town and University of Louisville | Date: 2017-07-26

Compounds, including quinoxaline derivatives of Formula (I), for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpn, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, pn1. Cancer cells have elevated levels of pn1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, whilst non-cancer cells are substantially unaffected by the inhibition of pn1s nuclear import activity.


Patent
University of Cape Town | Date: 2017-08-02

The invention provides a process for synthesising a compound of formula (V) wherein: formula (z) or a physiologically acceptable salt, tautomer, stereoisomer or mixture of stereoisomers thereof. The process utilizes a /V-benzyl protected histidine rather than the unprotected form of histidine. The process of the invention comprises the steps of: (a) deprotecting a /V-benzyl protected histidine of formula 11 to form A/-benzyl histidine of formula 12; (b) converting compound 12 to (S)-3-(1 -benzyl-1 H-imidazol-4-yl)-2-(dimethylamino)propanoic acid of formula 13; (c) converting compound 13 to (2S)-N,N,N-2-trimethylethanaminium-3-(1 -benzyl- 1H-imidazol-4-yl)propanoic acid of formula 14; (d) brominating the imidazole ring of the compound of formula 14 to form 5-bromohercynine lactone (reactive intermediate); and (e) converting the 5-bromohercynine lactone of step (d) to (p-amino-p- carboxyethyl)ergothioneine sulfide of formula 15. The process optionally further includes one of steps (f) to (h): (f) converting the compound of formula 15 to a sulfoxide; (g) converting the compound of formula 15 to a sulfone; or (h) converting the compound of formula 15 to ergothioneine (ESH).


Patent
South African Nuclear Energy Corporation and University of Cape Town | Date: 2017-08-02

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radionuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.


Patent
Mmv Medicines For Malaria Venture and University of Cape Town | Date: 2017-01-18

The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.


This invention relates to a method of classification of cancer type or subtype in a subject by detecting glycosyltransferase gene expression in a sample from the subject. In particular, where the method is for classification of cancer subtype in the subject the glycosyltransferase genes may be survival associated glycosyltransferase genes. The invention further relates to a kit comprising glycosyltransferase gene biomarkers for use with the method, and a method of treatment of cancer in a subject with the use of the method or kit of the invention.


Patent
University of Southampton and University of Cape Town | Date: 2016-12-28

The present invention relates to Surfactant Protein D (SP-D) or nucleic acids encoding SP-D or variants therof such as surfactant protein A or mannan binding lectin for use in the treatment and/or prevention of a parasitic infection. Methods for determining the presence of a parasitic infection by determining levels of SP-D in a sample are also disclosed. Also disclosed are helminths for treating allergy, inflammation or infection.


Patent
University of Cape Town | Date: 2017-04-19

The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.


An apparatus and method for determining the condition of an electricity-producing cell such as a fuel cell is disclosed. A signal is injected into an electricity-producing cell, a voltage and/or current response is measured, and the impedance response of the electricity-producing cell is calculated using the injected signal and the response. The injected signal is a broadband signal that includes a plurality of superimposed waveforms at different frequency set points across a frequency range. The distribution of the waveform frequency set points is linear at either or both of a lower portion and an upper portion of the frequency range, and is logarithmic at a mid-range of the frequency range. The response at each of the frequency set points are simultaneously obtained and the impedance response across the frequency range is calculated and used to determine a condition of the electricity-producing cell.


Patent
University of Cape Town | Date: 2017-01-04

The present inventors have identified plasma biomarkers which, alone or in combination, make it possible to diagnose peripartum cardiomyopathy (PPCM) in a patient with certainty. The assaying of these biomarkers can be easily carried out using a droplet of blood, for example taken from the end of a finger of a patient, or of blood plasma. These biomarkers are molecules known for the pro-angiogenic or anti-angiogenic effect thereof, more specifically fms-like tyrosine kinase 1 (sFlt-1), PlGF, VEGF and relaxin.

Loading University of Cape Town collaborators
Loading University of Cape Town collaborators